Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Conditions
Renal Cancer
Conditions: official terms
Carcinoma, Renal Cell - Kidney Neoplasms
Conditions: Keywords
ablation, quality of Life (QOL), kidney, registry, Ablation of Renal Masses Outcomes Registry (ARMOR), 13-116
Study Type
Observational [Patient Registry]
Study Phase
N/A
Study Design
Observational Model: Cohort
Intervention
Name: (EORTC QLQ-C30) questionnaire Type: Behavioral
Name: EuroQol EQ-5D 7-item questionnaire Type: Behavioral
Overall Status
Recruiting
Summary
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

Retrospective enrollment:

- Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal mass.

Prospective enrollment:

- Patients scheduled to undergo, rather than having undergone, percutaneous, open or laparoscopic energy ablation of a renal mass.

Exclusion Criteria:

- Patients not having undergone, or considered candidates for percutaneous, open or laparoscopic energy ablation of a renal mass

- Non-English speaking patients

- Patients under the age of 18.
Locations
University of Maryland Medical Center
Baltimore, Maryland, United States
Status: Recruiting
Contact: Richard Howard, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Jeremy Durack, MD - 212-639-4898
Thomas Jefferson University Hospital
Philadelphia,, Pennsylvania, United States
Status: Recruiting
Contact: Colette Shaw, MD
Rhode Island Hospital
Providence, Rhode Island, United States
Status: Recruiting
Contact: Damian Dupuy, MD
Start Date
June 2013
Completion Date
June 2018
Sponsors
Memorial Sloan Kettering Cancer Center
Source
Memorial Sloan Kettering Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page